i noticed new banner ad binge eating disorder pages last night first time one sophisticated ads becomes video clip click main message video clip binge eating disorder real medical disorder provides link web site bingeeatingdisorder go site click health care professionals link taken essentially massive infographic binge eating disorder descriptions known epidemiology theory mention treatment specific fda approved medication pharmaceutical company approved speculation coming advertisers analyze web traffic see well ad campaign accepted specifically usual outcry pharmaceutical companies making diagnoses order sell drugs course evil psychiatrists involved lot blowback occurs would easy cancel campaign take web site either come another campaign go traditional advertising much less politically adept audience namely physicians medical journals i admit brain graphic slice pizza replacing parietal lobe eye catching ad allows me make couple points first reason epidemics addictive drugs general process increase availability exposing people drug know genotypes risk general significant part population euphorigenic responses addictive drugs wider availability generally equates larger numbers users people risk addiction example i like use growing northern wisconsin back even though hippie generation main exposure remote areas alcohol marijuana flash forward years widespread availability practically drugs abuse rural areas including intravenous heroin anytime addictive drug comes marketplace risk level availability lead addiction complications addiction case first amphetamine epidemic marketing general use number disorders respond medication marketing products like benzedrine inhalers could easily abused end thousands amphetamine containing products moved schedule ii much tighter regulation second point fda clearly inadequate job preventing addiction complications addiction doubt main objective fda get pharmaceuticals marketplace soon possible although politicians like grandstand idea fda prevents release life saving drugs builds regulatory hurdles lead unnecessary expense appears less less evidence true politicians seem favor quicker release less regulation fairly clear fda minimal scientific requirements release multiple new opioids time opioid epidemic overdose deaths recommendations scientific committee would case point case point none new opioid drugs unique compound basically mixes matches old compounds patentable dose sizes various possibly tamper proof formulations even i type note i informed fda accepted application reviewing new drug combination extended release oxycodone naltrexone fda clearly lax approach potentially addictive compounds depend post marketing surveillance called rems risk evaluation mitigation strategies reasonable approach would use gatekeeper strategy monitor physicians complications prescribing controlled substances since agencies regulators levels seem believe teach physicians prescribe controlled substances equal low level skill time gatekeeper option past main fda approach post marketing surveillance basically waiting see happens case addictive drugs even worse idea risky medications post marketing surveillance depends reports physicians patients health care professionals reporting complication controlled substance much less likely happen number reasons physicians working addiction field may working settings higher standard confidentiality typical medical records time potential interpretation diversion inappropriate prescribing reporting less likely reasons post marketing surveillance good approach monitor new pharmaceutical see overprescribed abused good approach decades large databases compile prescriptions physician data typically sold pharmaceutical companies gauge success marketing efforts number prescriptions written time fda ran database looked real numbers trends prescribing would first hand knowledge many new vyvanse prescriptions written binge eating disorders potential prescription mills located could intervene years long decades long problem i conclude binge eating ad good advertising someone said addictive drug sells i think true terms place stimulants collective consciousness americans seen magical performance enhancing drugs good whatever ails i see pressure building primary care clinics vyvanse prescriptions binge eating disorder patients expressing severe disappointment hear clinic prescribe understand good advertising necessarily good medicine creating demand medication definite addictive potential seldom george dawson md dfapa